Teva, MedinCell Say FDA Approves Uzedy for Schizophrenia

Teva Pharmaceuticals and MedinCell said the US FDA approved Uzedy (risperidone) extended-release injectable suspension for schizophrenia in adults.

• Uzedy will be available in the US in the coming weeks
• “The approval of the first product formulated with our technology is a pivotal moment”: MedinCell CEO

To view the source of this information, click here

To contact the reporter on this story:
Greg Chang in San Francisco at gchang1@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli at cadusumilli@bloomberg.net

© 2023 Bloomberg L.P. All rights reserved. Used with permission.